Targeting the rich extracellular matrix of desmoplastic tumors has been successfully shown to normalize collagen and hyaluronan levels and re-engineer intratumoral mechanical forces, improving tumor perfusion and chemotherapy. As far as targeting the abundant cancer-associated fibroblasts (CAFs) in desmoplastic tumors is concerned, while both pharmacologic inhibition of the sonic-hedgehog pathway and genetic depletion of fibroblasts have been employed in pancreatic cancers, the results between the two methods have been contradictory. In this study, we employed vismodegib to inhibit the sonic-hedgehog pathway with the aim to i) elucidate the mechanism of how CAFs depletion improves drug delivery, ii) extent and evaluate the potential use of sonic-hedgehog inhibitors to breast cancers, and iii) investigate whether sonic-hedgehog inhibition improves not only chemotherapy, but also the efficacy of the most commonly used breast cancer nanomedicines, namely Abraxane® and Doxil®. We found that treatment with vismodegib normalizes the tumor microenvironment by reducing the proliferative CAFs and in cases the levels of collagen and hyaluronan. These modulations re-engineered the solid and fluid stresses in the tumors, improving blood vessel functionality. As a result, the delivery and efficacy of chemotherapy was improved in two models of pancreatic cancer. Additionally, vismodegib treatment significantly improved the efficacy of both Abraxane and Doxil in xenograft breast tumors. Our results suggest the use of vismodegib, and sonic hedgehog inhibitors in general, to enhance cancer chemo-and nanotherapy.
Introduction
Inefficient delivery of cytotoxic drugs to solid tumors can dramatically reduce the efficacy of chemotherapy and nanotherapy and thus, negatively affect the quality of life and survival of cancer patients. This can explain in large part why standard therapies many times fail to treat desmoplastic cancers, i.e., tumors abnormally rich in stromal components such as breast and pancreatic cancers, even though these agents are potent enough to eradicate cancer cells in in vitro systems. Effective delivery of drugs to solid tumors is hindered by abnormalities in the structure of the tumor vasculature, which can drastically reduce tumor perfusion and as a result the systemic delivery of the drug [1, 2] .
In desmoplastic tumors, in particular, mechanical interactions among rapidly proliferating cancer cells, cancer associated fibroblasts (CAFs), extracellular matrix (ECM) fibers, primarily collagen and hyaluronan, and the surrounding normal tissue lead to accumulation of intratumoral solid stresses, causing vessel compression and hypo-perfusion [2] [3] [4] [5] [6] . To improve blood vessel functionality and treatment efficacy, already approved drugs with anti-fibrotic properties have been repurposed (e.g., losartan, tranilast, pirfenidone) and it has been shown that these drugs can normalize the microenvironment of breast and pancreatic tumors to improve the delivery of chemotherapy and nanomedicine [7] [8] [9] . Importantly, this strategy has already reached clinical trials (clinicaltrials.gov identifier: NCT01821729) and the first results of a phase-II trial for the use of losartan to enhance therapy in pancreatic cancer patients confirm the preclinical findings [10] .
Apart from the use of anti-fibrotic drugs, pertinent studies have employed inhibitors of the Sonic Hedgehog (SHH) signaling pathway to achieve pharmacologic depletion of CAFs in pancreatic cancers. Inhibition of SHH signaling using saridegib was shown to reduce proliferation and number of CAFs in mouse models of pancreatic cancer, improve blood vessel functionality and eventually the efficacy of gemcitabine [11] . Despite these encouraging data, however, saridegib failed in a phase-II clinical trial for previously untreated patients with metastatic pancreatic cancer when combined with gemcitabine [12] . Similarly, more recent phase-II clinical trials in an unselected cohort of patients with metastatic pancreatic cancer indicated that, while modestly improved, combination of vismodegib and gemcitabine did not result in a statistically significant increase in overall survival compared to gemcitabine alone [13] . However, these results could be due to different reasons, such as intrinsic resistance to gemcitabine as increased delivery of a drug might not benefit patients if cancer cells are or become resistant to that drug, or these cancers are already at such an advanced stage for survival improvement to be significantly demonstrated. Moreover, random selection of patients could also affect clinical trial results, since one would expect vismodegib to be particularly beneficial for highly desmoplastic, fibroblast-rich pancreatic tumors.
Additionally, a series of recent in vivo studies have shown that deletion of CAFs by genetic manipulation in mouse models induces immunosuppression and promotes tumor progression in pancreatic cancers [14, 15] . Therefore manipulation of CAFs has been shown to both promote and restrain tumor progression, but any comparison between genetic deletion and pharmacologic depletion should be viewed with caution and take into account that these methods significantly differ from each other as:
i. Genetic deletion is chronic and effects of genetic deletion are not reversible. On the other hand, pharmacologic depletion is acute and effects are reversible when the treatment stops. ii. Pharmacological agents could be delivered specifically to the tumor site while genetic deletion might affect the entire body. iii. Genetic deletion might improve drug delivery and increase hypoxia, whereas pharmacologic depletion improves drug delivery and decreases hypoxia.
In this study, we revisited the use of SHH inhibitors to target CAFs with the aim to i) elucidate the mechanism of how CAFs depletion improves drug delivery, ii) extent and evaluate the potential use of SHH inhibitors to breast cancers, and iii) investigate whether SHH inhibition can improve not only chemotherapy, but also the efficacy of the most commonly used breast cancer nanomedicines, namely Abraxane® and Doxil®. To achieve our aims, we employed vismodegib (Erivedge®) in mouse tumor models for pancreatic and breast cancers to explore its ability to normalize the tumor microenvironment, decrease solid stress levels and improve tumor perfusion and therapeutic outcomes.
Vismodegib is the first oral medication approved by the US Food and Drug Administration in 2012 for adults with metastatic or locally advanced Basal Cell Carcinoma that has recurred after surgery or for patients who are not candidates for surgery or radiation. Previous studies have shown that administration of vismodegib in a mouse model of medulloblastoma and in xenograft models of primary human tumors, including colorectal and pancreatic carcinoma, inhibits SHH pathway and exerts antitumor activity [16] [17] [18] [19] .
To elucidate the mechanism by which depletion of CAFs improves drug delivery, we initially hypothesized that depleting stromal cells in primary pancreatic tumors will reduce solid stresses and improve the functionality of tumor blood vessels. To investigate this, we employed two human pancreatic cancer cell lines, namely MiaPaCa2 and BxPC3 to develop xenograft tumor models in immunodeficient mice. We show that vismodegib reduces solid stresses, decreases interstitial fluid pressure (IFP), improves perfusion, increases delivery of chemotherapy and improves therapeutic outcomes. Furthermore, we show that these observations are not only due to the reduction in the activity of CAFs but also due to the decrease in collagen and hyaluronan tumor content due to SHH signaling pathway inhibition and downregulation of downstream key effector genes Gli1 and Gli2. Finally, we developed an orthotopic xenograft breast tumor model, using the human breast cancer cell line MCF10CA1a, to study the effect of combining vismodegib with two clinically approved nanoparticles of different sizes, Abraxane (10 nm) and Doxil (100 nm), and show that vismodegib can also enhance the efficacy of these common cancer nanomedicines.
Materials and methods

Cell culture
MiaPaCa2 human pancreatic cancer cell line and BxPC3 human primary pancreatic adenocarcinoma cell line were purchased from ATCC and were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 1% antibiotics. MCF10CA1a human breast cancer cell line was obtained from the Karmanos Cancer Institute (Detroit, MI, USA) and maintained as previously described [20] .
Drugs and reagents
Vismodegib (GDC-0449, Erivedge) was purchased from Selleckchem and the compound was formulated in a 10 mg/ml suspension in MCT (0.5% methylcellulose, 0.2% Tween 80), as previously described [16] . Gemzar (gemcitabine, Lilly) was dissolved in 0.9% NaCl (12.5 mg/ml stock). Doxil (pegylated liposomal doxorubicin, Janssen Pharmaceuticals) was purchased as already made solution (2 mg/ml) and Abraxane (albumin-bound paclitaxel, Celgene) was solubilized in 0.9% NaCl in final stock concentration of 5 mg/ml.
Animal tumor models and treatment protocols
Xenograft pancreatic tumor models were generated by subcutaneous implantation of 2 × [8, [21] [22] [23] . During the course of each experiment, tumor growth was monitored daily and the planar dimensions (x, y) were measured using a digital caliper. Tumor volume was calculated using the volume of an ellipsoid and assuming that the third dimension, z, is equal to x y . All in vivo experiments were conducted in accordance with the animal welfare regulations and guidelines of the Republic of Cyprus and the European Union under a license acquired by the Cyprus Veterinary Services (No CY/EXP/PR.L1/2014), the Cyprus national authority for monitoring animal research.
To study alterations in the tumor microenvironment, right before the end of each treatment protocol, animals were anesthetized by i.p. injection of Avertin (200 mg/kg) and interstitial fluid pressure was measure using the wick-in-needle technique [3, 24, 25] . Next, mice were injected intracardially with 100 μl biotinylated lectin (1 mg/ml, Vector Labs), which was allowed to distribute throughout the body for 7 min [7] [8] [9] . Finally, mice were sacrificed via CO 2 inhalation and tumors were excised for measurement of mechanical properties and/or histological analysis.
Fluorescent immunohistochemistry and vessel perfusion histology
MiaPaCa2 and BxPC3 pancreatic tumors were excised from mice, fixed in 4% paraformaldehyde, dehydrated through an ethanol series and embedded in paraffin wax before sectioning (7-mm thickness). Hematoxylin and eosin (H & E) and Masson's trichrome staining were performed using previously described methods [11, 20] . For immunofluorescence analysis, samples were embedded in optimal cutting temperature compound (OCT) upon tumor excision. Transverse 40 μm-thick tumor sections were made using the Tissue-Tek Cryo3 (SAKURA) and immunostained using antibodies against collagen I (ab34710), CD31 (BD553370) and hyaluronan (ab53842) and then detected using appropriate secondary fluorescent antibodies. For alpha-smooth muscle actin (a-SMA) (ab7817) and Ki67 (ab15580) staining, tumors were fixed in 4% paraformaldehyde and embedded in paraffin before sectioning, as previously described [8, 11, 20] .
For blood vessel perfusion analysis, mice were slowly injected with 100 μl of 1 mg/ml biotinylated Lycopersicon esculentum (tomato) lectin (Vector Labs) via intracardiac injection 7 min prior to euthanization and tumor removal. Upon excision, tumors were fixed in 4% paraformaldehyde, embedded in OCT and frozen. Transverse 40 μm-thick tumor sections were produced and stained with an antibody CD31. Streptavidin-conjugated and fluorescently-labeled secondary antibodies against lectin and CD31 were used to detect these antigens, respectively.
Images from anti-collagen I, anti-CD31, anti-hyaluronan and antibiotin-stained sections were analyzed based on the area fraction of positive staining. To avoid any bias, the analysis was performed automatically using a previously developed in-house code in MATLAB (MathWorks, Inc., Natick, MA, USA) [3] . Images from five different sections per tumor (from the interior and the periphery) were taken using an Olympus BX53 fluorescent microscope at 10 × magnification and were analyzed by keeping the analysis settings and thresholds identical for all tumors.
Biodistribution analysis
For biodistribution analysis, 20 mg/kg doxorubicin (Actavis) was injected intravenously in control or vismodegib-treated animals and 4 h post-injection they were sacrificed. Seven animals per group were tested (n = 7). The tumors and respective tissues were excised from the mice and were stored at − 80°C until extraction and further analysis. For doxorubicin extraction from tumors and tissues, a previously described method was used [8, 9, 26] . Doxorubicin concentration in tissue sample homogenates was determined by quantification of fluorescence intensity (Ex.: 470 nm, Em: 590 nm).
RNA isolation, cDNA synthesis, and real-time polymerase chain reaction
Total RNA was isolated from pancreatic tumors using standard Qiazol-based protocol (Qiagen) and cDNA synthesis was performed using reverse transcriptase III (RT-III) enzyme and random hexamers (Invitrogen). Real-time polymerase chain reaction (PCR) was performed using Sybr Fast Universal Master Mix (Kapa) and calculation of changes in gene expression between compared groups was performed using the ΔΔCt method, as previously described [27] . Mouse-specific primers were used for gene expression analysis in stromal cells from MiaPaCa2 and BxPC3 tumors, while human-specific primers were used for gene expression analysis in MiaPaCa2 and BxPC3 cancer cells in tumors (Supplementary Table 1 ). All reactions were performed using a CFX-96 real-time PCR detection system (Biorad) under the following conditions: 95°C for 2 min, 95°C for 2 s, 60°C for 20 s, 60°C for 1 s, steps 2-4 for 39 cycles.
Mechanical testing measurements for calculation of elastic modulus and hydraulic conductivity
The elastic modulus was calculated using an unconfined compression experimental protocol. Following tumor excision, tumor specimens 3 × 3 × 2 mm (length × width × thickness) were loaded on a high precision mechanical testing system (Instron, 5944, Norwood, MA, USA) and compressed to a final strain of 30% with a strain rate of 0.05 mm/min. The elastic modulus was calculated from the slope of the stress-strain curve.
For the calculation of the hydraulic conductivity stress relaxation experiments were performed in compression. Specimens underwent four cycles of testing for each of which a 5% compressive strain was applied for 1 min, followed by a 10-min hold. Subsequently, the hydraulic conductivity was calculated by fitting a mathematical biphasic model of soft tissue mechanics [28, 29] to the experimental data, as previously described [8, 9] .
Results
Vismodegib reduces functionality of CAFs in vivo
First, to validate that vismodegib targets CAFs in vivo, mice bearing MiaPaCa2 and BxPC3 tumors were treated with 40 mg/kg vismodegib. Animals orally received vismodegib on a daily basis starting 35 days (MiaPaCa2) or 4 days (BxPC3) post-implantation of cancer cells, for a period of 25 days or 23 days, respectively, according to previous studies [16, 17, [30] [31] [32] [33] . Upon tumor excision, co-immunofluorescence analysis was performed on tumor sections to detect alpha-smooth muscle actin (a-SMA), as a CAF's marker, and Ki-67 to identify the proliferating cells. Then, the tumor area fraction in which a-SMA and Ki-67 staining overlapped (a-SMA/Ki67 positive cells) was quantified and compared between the two groups, to detect the presence of actively proliferating 
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CAFs (Fig. 1A ) [11] . We found that vismodegib significantly reduced the fraction of proliferating CAFs in vivo (Fig. 1B) . Fraction of proliferating CAFs as a function of total a-SMA are presented in Supplementary Fig. S1 . Furthermore, H & E as well as Masson's trichrome staining of MiaPaCa2 and BxPC3 tumor sections indicated that vismodegib treatment resulted in a more sparse cell network and decreased collagen fibers compared to controls, presumably due to the reduction in the number of CAFs ( Supplementary Fig. S2 ) as previously reported [11, 34] .
Vismodegib remodels the tumor ECM by reducing collagen and hyaluronan levels
Additionally, it is possible that vismodegib could also indirectly reduce tumor ECM content through inhibition of CAFs and suppression of collagen and hyaluronan synthesis. To determine the effect of vismodegib on tumor ECM components, we performed immunofluorescence analysis of tumor cryosections followed by area fraction quantification. We found that vismodegib treatment decreased collagen content in MiaPaCa2 by 20%, whereas no change was observed in BxPC3 tumors ( Fig. 2A, E) , which could be attributed to differences in the genetic background of these cells. On the other hand, area fraction quantification indicated that hyaluronan levels were decreased in both MiaPaCa2 and BxPC3 tumors by 23% and 32%, respectively, compared to control-treated tumors (Fig. 2B, F) . Similar effects on collagen and hyaluronan levels were observed when MiaPaCa2 tumors received a higher dose of vismodegib (100 mg/kg) ( Supplementary Fig. S3 ).
Subsequently, we investigated the effect of vismodegib on the functionality of tumor blood vessels. We measured the percentage of perfused blood vessels of the control and vismodegib-treated tumors by staining tissue cryosections with antibodies against the endothelial marker CD31 and biotinylated lectin, which marks the functional tumor vessels. The fraction of perfused vessels was calculated based on the ratio of the area of biotinylated lectin positive (+) to the CD31 positive (+) vessels. We found that in vismodegib-treated mice the fraction of perfused vessels was significantly increased in both MiaPaCa2 and BxPC3 tumors by approximately 2.5-fold and 50%, respectively, compared to controls (Fig. 2G) . Furthermore, the total area of vessels (CD31+ area) in both pancreatic tumor models remained unaffected (Fig. 2H) . Similar results on perfused vessels as well the total number of vessels were obtained when MiaPaCa2 tumors received 100 mg/kg vismodegib ( Supplementary Fig. S3 ). Overall, our data suggest that vismodegib can improve perfusion without affecting tumor angiogenesis.
Vismodegib treatment alleviates solid and fluid stresses
Subsequently, to further explore the potential of vismodegib to normalize the tumor microenvironment, we performed detailed analysis of the mechanical properties of the tumors. As it has been previously demonstrated, improved perfusion is achieved by alleviation of intratumoral solid stresses [7] [8] [9] . Furthermore, reduction of ECM fibers has the potential to alleviate IFP, which can enhance delivery of drugs [1] . Therefore, we carried out experiments to investigate whether vismodegib treatment affects solid stresses and IFP. We performed ex vivo stress-strain experiments under compression on vismodegib or controltreated pancreatic tumors (Fig. 3A, left) , which revealed that the mean values of the elastic modulus were decreased in both tumor types, presumably owing to hyaluronan reduction that resist compressive strains. However, the change in the elastic modulus was statistically significant only for the BxPC3 tumors (Fig. 3B) . In addition, we examined the effect of vismodegib on tumor fluid phase features and particularly on the interstitial hydraulic conductivity and IFP. To calculate the hydraulic conductivity, we performed ex vivo stress-relaxation experiments during which the tumor is rapidly squeezed by two platens and held to a constant compression so that the interstitial fluid will equilibrate, resulting in its partial leakiness from the tumor (Fig. 3A, right) . Hydraulic conductivity is a measure of the easiness by which interstitial fluid percolates in the tumor ECM and, thus, the higher the conductivity the more fluid will leak from the tumor during compression. The values of the hydraulic conductivity can be extracted from the experiments using mathematical modeling [8, 9] . IFP was Fig. 3. Vismodegib acts as a stress-alleviating agent. (A) Schematic of the unconfined compression experiment. Desmoplastic tumors become stiff as they grow, exhibiting a higher elastic modulus and resisting stronger to compression. Desmoplasia reduces tumors hydraulic conductivity, resisting to fluid flow through their mass and thus, less fluid exits the tissue during compression. (B) Vismodegib-treated tumors in BxPC3 decreased the elastic modulus compared to control treatment (p = 0.002) whereas in MiaPaCa2 had no effect. Vismodegib-induced reduction in ECM content resulted in lower values of hydraulic conductivity of the tumor interstitial space (p = 0.005 for MiaPaCa2 and p = 0.04 for BxPC3) (C), which in turn caused alleviation of the interstitial fluid pressure (p = 4E-9 for MiaPaCa2 and p = 5E-5 for BxPC3) (D). Asterisks indicate statistically significant difference between compared groups (n = 8-10).
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measured using the wick-in-needle technique [24] . We found that treatment with vismodegib significantly increased hydraulic conductivity by approximately 4-fold in both MiaPaCa2 and BxPC3 tumors (Fig. 3C ) and alleviated IFP by 2.5 and 3-fold, respectively (Fig. 3D ).
Vismodegib improves the efficacy of chemotherapy
Based on our results, we hypothesized that vismodegib can improve the efficacy of chemotherapy. To investigate our hypothesis, we performed tumor growth studies in MiaPaCa2 and BxPC3 pancreatic tumors. Mice orally received mock treatment or vismodegib (40 mg/kg) starting 35 days (MiaPaCa2) and 4 days (BxPC3) post-implantation of cancer cells, whereas administration of gemcitabine (50 mg/kg, i.p.) begun on day 45 (MiaPaCa2) or day 11 (BxPC3). Tumor volume was measured throughout the treatment period. In our study, we found that vismodegib alone or gemcitabine alone did not influence primary tumor growth (Fig. 4) . However, combinatorial treatment with vismodegib and gemcitabine dramatically decreased tumor volume in MiaPaCa2 model and significantly delayed tumor growth in BxPC3. A higher dose of vismodegib (100 mg/kg) was also tested in combination with gemcitabine in MiaPaCa2 tumors which resulted in a similar growth effect compared to the lower dose (data not shown). Therefore, targeting the tumor microenvironment with vismodegib significantly improved the therapeutic outcome of standard chemotherapy.
Vismodegib increases delivery of doxorubicin to tumors but not to normal tissues
To verify that normalization of the tumor microenvironment increases delivery of drugs, we performed biodistribution analysis in MiaPaCa2 tumors, following the same treatment protocol as in the 5 . Vismodegib increases intratumoral delivery of doxorubicin. Quantification of doxorubicin (Dox) concentration in control and vismodegib-treated MiaPaCa2 pancreatic tumors as well as in kidney, liver and heart tissues. Doxorubicin (20 mg/kg) was injected intravenously to the animals 4 h prior to sacrifice. Vismodegib increased the delivery of doxorubicin by 2-fold in vismodegib-treated compared to control-treated tumors (p < 0.05, n = 9). No significant differences were observed in drug delivery to normal tissues. Asterisk indicates statistically significant differences between compared groups (p < 0.05). previous experiments. More specifically, 20 mg/kg of doxorubicin was injected intravenously (i.v.) to animals 4 h prior to sacrifice. Doxorubicin concentration in tissue sample homogenates was determined by quantification of fluorescence intensity and calculated based on a standard curve generated by addition and measurement of known amounts of doxorubicin to normal tissue homogenates of nontreated animals. Our data indicate that there was a significant 2-fold increase in doxorubicin concentration in vismodegib-treated tumors compared to the control group, whereas there was no effect in the delivery of the drug to any normal tissue tested, including heart, liver or kidney (Fig. 5 ).
Vismodegib inhibits sonic hedgehog signaling in stromal cells
Based on previous studies suggesting that vismodegib exerts its effects by suppressing the SHH signaling pathway in CAFs [11] , we wanted to investigate and confirm potential gene expression changes in our in vivo tumor models. To this end, we performed real-time PCR analysis for the expression of selected genes in both MiaPaCa2 and BxPC3 tumors. We found that while vismodegib was able to suppress the expression of the two major SHH pathway downstream effector genes, Gli1 and Gli2, in stromal genes it had no effect on the expression of these genes in human MiaPaCa2 cancer cells (Fig. 6) . Similar stromal-specific effects were also observed for Gli1 expression in BxPC3 tumors ( Supplementary Fig. S4 ). This evidence collectively suggests that vismodegib is able to remodel the pancreatic tumor microenvironment primarily by targeting SHH signaling in host stromal cells which, in large part, are comprised by CAFs.
Vismodegib improves the efficacy of Abraxane and Doxil
Finally, we wanted to extend our analysis to other desmoplastic tumors as well to test the ability of vismodegib to also enhance the efficacy of common cancer nanomedicines. To this end, we employed an orthotopic breast xenograft tumor model, using human MCF10CA1a breast cancer cells implanted in the mammary fat pad of CD1 nude mice and investigated the effect of vismodegib on the efficacy of the most common nanomedicines used for the treatment of breast cancer, Abraxane and Doxil. Abraxane is a 130 nm albumin-bound paclitaxel that shrinks to 10 nm following dilution to plasma [21] and Doxil is an 100 nm pegylated liposomal doxorubicin. In this model, mice orally received mock treatment or vismodegib 4 days post-implantation of cancer cells, whereas administration of nanoparticles begun on day 14 and tumor volume was measured throughout the treatment period. We found that vismodegib, Doxil (3 mg/kg, i.v.) or Abraxane (20 mg/kg, i.v.) alone did not influence primary tumor growth (Fig. 7) . On the other hand, combined administration of vismodegib and Abraxane significantly delayed tumor growth compared to Abraxane alone. Similarly, combination of Doxil and vismodegib significantly reduced tumor volume compared to monotherapy (Fig. 7) . Consistent with our previous findings in pancreatic tumor models, vismodegib also decreased IFP and the elastic modulus of breast tumors ( Supplementary  Fig. S5 ).
Discussion
In the current study, we aimed to investigate the effect of targeting CAFs in the efficacy of chemo-and nanotherapeutic drugs, using the SHH pathway inhibitor vismodegib, in different xenograft mouse models of desmoplastic pancreatic and breast cancers. Our data indicate that vismodegib primarily targets CAFs by inhibiting their proliferation rate. This effect appears to be mediated by suppression of the SHH signaling pathway, as evident by downregulation of Gli1 and Gli2 gene expression, in stromal but not human pancreatic cancer cells in our xenograft mouse models. These data are consistent with previous studies suggesting that vismodegib is an effective inhibitor of the SHH pathway in stromal cells and acts to suppress the functionality of CAFs in pancreatic cancers [11] . Our data presented here extend previous findings and show that depletion of CAFs has profound effects in remodeling of the tumor microenvironment, thus promoting solid and fluid stress alleviation in vismodegib-treated pancreatic and breast tumors, which enhances drug delivery and significantly improves the efficacy of chemotherapy and common nanomedicines. Our findings suggest that this is mediated by both the elimination of CAFs from the tumor mass as well as by reduction in the amount of ECM components which, in large part, are produced by the CAFs [34, 35] .
Most importantly, and despite the fact that recent clinical trials have failed to show that combining vismodegib with gemcitabine can cause significant enhancement in treatment efficacy and overall survival in patients with metastatic pancreatic cancer [13] , our novel findings suggest that similar studies could be worth revisiting in a more targeted group of patients with highly desmoplastic, fibroblast-rich tumors, rather than in unselected cohorts. Furthermore, our data using orthotopic xenograft models for human breast cancer strongly suggest that vismodegib-induced depletion of CAFs and remodeling of the ECM can also dramatically enhance the efficacy of clinically approved nanomedicines of various sizes, such as Abraxane and Doxil, which are known to have significantly less adverse effects compared to traditional chemotherapies. Similar enhancement in the efficacy of nanotherapy in breast cancer have recently been shown by other stress alleviating agents, such as the TGFβ pathway inhibitors tranilast and pirfenidone as well as the angiotensin II receptor blocker losartan [8, 9, 22] . Therefore, our data collectively suggest that vismodegib-induced CAFs depletion normalizes the microenvironment of desmoplastic tumors and induces alleviation of intratumoral stresses, increasing blood vessel perfusion and drug delivery. Since vismodegib has been already approved for clinical use, it could be combined with common chemoand nanotherapeutic drugs in selected patients with desmoplastic pancreatic and breast cancers to significantly improve treatment , or vismodegib in combination with either Doxil or Abraxane, as described above. Abraxane alone had no effect on tumor volume, compared to combined administration of vismodegib and Abraxane, which significantly delayed tumor growth (p = 0.02 on day 28, n = 6-8). Additionally, whereas Doxil (3 mg/kg) monotherapy had no effect, combination of vismodegib and Doxil significantly decreased tumor volume (p = 2E-6 on day 28, n = 6-8) compared to Doxil alone. Asterisks indicate a statistically significant difference between compared groups (p < 0.05).
efficacy and overall survival. We suggest that such findings could directly lead to Phase II clinical trials in targeted groups of patients to test the efficacy of this therapeutic strategy in humans. Finally, anti-fibrotic drugs such as losartan, tranilast and pirfenidone have been also used successfully to normalize the desmoplastic tumor microenvironment by targeting the tumor ECM [7] [8] [9] . Here, we showed that direct targeting of CAFs can cause an indirect decrease in ECM content, suggesting that vismodegib can modulate both components of tumor stroma.
